In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 411 to 420 of 444

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]	Technology appraisal guidance	TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]	Technology appraisal guidance	12 June 2026
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Highly specialised technology	TBC
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351	Technology appraisal guidance	TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406	Technology appraisal guidance	TBC
Total hip arthroplasty using the superpath approach for osteoarthritis	Interventional procedures guidance	TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557	Technology appraisal guidance	TBC
Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation	Interventional procedures guidance	25 February 2026
Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension	Interventional procedures guidance	25 March 2026

Results per page